Understanding and targeting genetic weaknesses in complex acute myeloid leukemia
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML
This research aims to find new ways to treat acute myeloid leukemia (AML) that has complex genetic changes, which often makes it harder to treat.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11124245 on NIH RePORTER |
What this research studies
We are looking closely at the genetic makeup of AML cells from many patients with complex karyotype AML, a type of leukemia with many genetic changes. By using advanced genetic mapping, we hope to understand why these cells grow and resist standard treatments. We will then create models of this specific type of AML to test new treatment strategies that target the unique weaknesses found in these cancer cells. Our goal is to develop therapies that can overcome the resistance to chemotherapy often seen in this challenging form of leukemia.
Who could benefit from this research
Good fit: This research is most relevant to patients diagnosed with acute myeloid leukemia who have complex karyotype, meaning their cancer cells show three or more genetic abnormalities.
Not a fit: Patients with other types of leukemia or those whose AML does not have complex genetic changes may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatments for patients with complex karyotype acute myeloid leukemia, a form of the disease with a very poor prognosis.
How similar studies have performed: Preliminary data suggests that targeting metabolic changes linked to p53 loss can encourage AML cells to differentiate, indicating a promising new approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lowe, Scott W. — Sloan-Kettering Inst Can Research
- Study coordinator: Lowe, Scott W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.